CLEVELAND, June 05, 2023 (GLOBE NEWSWIRE) -- NovelMed Therapeutics, Inc. announced today topline results from First-in-Human Phase I clinical trial of its complement blocker monoclonal anti-Properdin ...

In the alternative pathway, C3b binds to Factor B. Factor D releases Factor Ba from Factor B bound to C3b. The complex of C3b (2)Bb is a protease which cleaves C5 into C5b and C5a. C5 convertase is ...

Scientists from the Hong Kong University of Science and Technology (HKUST) have recently discovered a non-classical nucleation process that can greatly facilitate ice formation on foreign surfaces.

Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...

The classical complement pathway typically requires antigen—antibody complexes (immune complexes) for activation (specific immune response), whereas the alternative pathway can be activated by C3 ...

Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, No. 27 (Jul. 6, 2004), pp. 10127-10131 (5 pages) The lectin complement pathway in innate immunity is closely ...

The lectin pathway is the third pathway in the complement cascade, discovered after the classical and alternative pathways. It more closely resembles the classical pathway due to similar binding ...